The present study aimed to systematically evaluate the anticancer effects of the PARP1 inhibitor PJ34 and the natural polyphenol curcumin, administered alone and in combination, in platinum-sensitive and relatively platinum-resistant ovarian cancer models, with an emphasis on quantitative synergy assessment and functionally supported, hypothesis-generating mechanistic insight.<h4>Materials and methods</h4>Cell viability was evaluated using the MTT assay, and IC<sub>50</sub> values were derived from dose-response curves. The gene discussed is PARP1; the disease is ovarian carcinoma.